UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan

Tomoko Yoshihama, Akira Hirasawa, Hiroyuki Nomura, Tomoko Akahane, Yoshiko Nanki, Wataru Yamagami, Fumio Kataoka, Eiichirou Tominaga, Nobuyuki Susumu, Taisei Mushiroda, Daisuke Aoki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.

Original languageEnglish
Pages (from-to)170-174
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume47
Issue number2
DOIs
Publication statusPublished - 2017 Feb 1

Fingerprint

irinotecan
Carcinoma
Genotype
Disease-Free Survival
Recurrence
Ovarian Neoplasms
Survival Rate

Keywords

  • Irinotecan
  • Ovarian cancer
  • Pharmacogenomics
  • UGT1A1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. / Yoshihama, Tomoko; Hirasawa, Akira; Nomura, Hiroyuki; Akahane, Tomoko; Nanki, Yoshiko; Yamagami, Wataru; Kataoka, Fumio; Tominaga, Eiichirou; Susumu, Nobuyuki; Mushiroda, Taisei; Aoki, Daisuke.

In: Japanese Journal of Clinical Oncology, Vol. 47, No. 2, 01.02.2017, p. 170-174.

Research output: Contribution to journalArticle

Yoshihama, Tomoko ; Hirasawa, Akira ; Nomura, Hiroyuki ; Akahane, Tomoko ; Nanki, Yoshiko ; Yamagami, Wataru ; Kataoka, Fumio ; Tominaga, Eiichirou ; Susumu, Nobuyuki ; Mushiroda, Taisei ; Aoki, Daisuke. / UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. In: Japanese Journal of Clinical Oncology. 2017 ; Vol. 47, No. 2. pp. 170-174.
@article{ae2a7366235f469c88a9ddb3a9ac070d,
title = "UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan",
abstract = "We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.",
keywords = "Irinotecan, Ovarian cancer, Pharmacogenomics, UGT1A1",
author = "Tomoko Yoshihama and Akira Hirasawa and Hiroyuki Nomura and Tomoko Akahane and Yoshiko Nanki and Wataru Yamagami and Fumio Kataoka and Eiichirou Tominaga and Nobuyuki Susumu and Taisei Mushiroda and Daisuke Aoki",
year = "2017",
month = "2",
day = "1",
doi = "10.1093/jjco/hyw163",
language = "English",
volume = "47",
pages = "170--174",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan

AU - Yoshihama, Tomoko

AU - Hirasawa, Akira

AU - Nomura, Hiroyuki

AU - Akahane, Tomoko

AU - Nanki, Yoshiko

AU - Yamagami, Wataru

AU - Kataoka, Fumio

AU - Tominaga, Eiichirou

AU - Susumu, Nobuyuki

AU - Mushiroda, Taisei

AU - Aoki, Daisuke

PY - 2017/2/1

Y1 - 2017/2/1

N2 - We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.

AB - We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.

KW - Irinotecan

KW - Ovarian cancer

KW - Pharmacogenomics

KW - UGT1A1

UR - http://www.scopus.com/inward/record.url?scp=85015767664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015767664&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyw163

DO - 10.1093/jjco/hyw163

M3 - Article

C2 - 28173214

AN - SCOPUS:85015767664

VL - 47

SP - 170

EP - 174

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -